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Human APOBEC3G (hA3G) has been identified as an anti-HIV cellular factor. As a counter measure, the HIV-1 protein Vif causes the
degradation of hA3G by binding to it and directing it to the cellular proteasome. In this work, we have used hA3G deletion mutants to map the region
in hA3G required for its degradation by Vif to hA3G amino acids 105–245, the linker region between the two zinc coordination motifs. A small
fragment of hA3G containing only amino acids 105–245 will undergo Vif-induced degradation. However, while amino acids 105–156 of hA3G are
required for Vif interaction with hA3G, they are not themselves sufficient for hA3G degradation, a process that further requires amino acids 157–245.
While expression of hA3G fragments 1–156 or 157–384 (but not 246–384) can dominantly inhibit the Vif-mediated degradation of full-length
hA3G, only the N-terminal fragment inhibits the Vif/hA3G interaction. Inhibition of hA3G degradation by the C-terminal hA3G fragment 157–384
appears to be related to its ability to prevent the polyubiquitination of hA3G induced by Vif, a process that is required for Vif-mediated proteosomal
degradation of hA3G. Non-permissive cells stably expressing hA3G 1–156 or hA3G 157–384 are able to inhibit the replication of wild-type HIV-1,
thereby verifying the inhibitory effect of these fragments upon Vif-mediated hA3G degradation and suggesting their potential in anti-HIV-1 therapy.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; APOBEC3G; Vif; Polyubiquitination; Proteasome-dependent degradationIntroduction
Vif (virion infectivity factor) is a 190–240 amino acid protein
that is encoded by all of the lentiviruses except for equine
infectious anemia virus (Dettenhofer et al., 2000; Fisher et al.,
1987; Gabuzda et al., 1992; Gibbs et al., 1994; Kan et al., 1986;
Lee et al., 1986; Madani and Kabat, 1998; Simon et al., 1998;
Simon and Malim, 1996; Sodroski et al., 1986; Strebel et al.,
1987; von Schwedler et al., 1993). Vif is required for the human
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and H9, but is not required in other “permissive” cell types, such
as SupT1 and Jurkat cells (Fisher et al., 1987; Gabuzda et al.,
1992; Strebel et al., 1987). Non-permissive cells contain a
protein called human APOBEC3G (apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-like 3G, hereafter referred
to as hA3G), which prevents HIV-1 replication in the absence of
Vif (Sheehy et al., 2002). hA3G belongs to an APOBEC su-
perfamily containing at least 10 members, which share a
cystidine deaminase motif (a conserved His-X-Glu and Cys-X-
X-Cys Zn2+ coordination motif) (Jarmuz et al., 2002). Vif is able
to bind to hA3G (Mariani et al., 2003) and can reduce both the
cellular expression of hA3G and its incorporation into virions
(Kao et al., 2003). This reduction in cellular expression has been
attributed to both the inhibition of hA3G translation and to its
degradation in the cytoplasm by Vif (Stopak et al., 2003).
Fig. 1. The ability of mutant hA3G to be degraded by Vif and bind to Vif.
Plasmids coding for HA-tagged N- and C-terminal hA3G deletion mutants were
transfected into 293T alone or co-transfected with the plasmid coding for Vif.
(A) Graphic representation of the wild-type and mutant hA3G variants tested.
The filled rectangles represent the two catalytic sites in hA3G, and the numbers
represent the amino acid positions. (B) Western blots of lysates of transfected
cells probed, respectively, with anti-HA (top) and anti-β-actin (bottom). The
expression ratio of the different hA3G variants in the presence or absence of Vif
was determined, normalized to a ratio of 1.00 for wild-type hA3G, and listed at
the bottom of the upper panel. (C) Western blots of cell lysates (top) or anti-HA
immunoprecipitates (bottom) from cell lysates probed with anti-Vif.
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rapid degradation of hA3G by a proteasome-dependent mech-
anism (Yu et al., 2003).
Vif interacts with cytoplasmic hA3G as part of a Vif–Cul5–
SCF complex, resulting in the ubiquitination of hA3G and its
proteosomal degradation (Yu et al., 2003). The SLQ(Y/F)LA
motif located at the C-terminal of Vif is similar to the most
conserved sequence in the BC-box regions of the suppressors of
cytokine signaling (SOCS) protein (Kile et al., 2002). It is well
known that BC-box proteins act as adaptors that link proteins that
are being targeted for rapid degradation to a multisubunit E3
ubiquitin-protein isopeptide ligase (Pickart, 2001). Thus, muta-
tions of the SLQ(Y/F)LA have no effect on association between
Vif and hA3G, but do inhibit Vif-mediated degradation (Marin
et al., 2003; Yu et al., 2003). A H-X(5)-C-X(17–18)-C-X(3–5)-H
motif that is highly conserved among all primate lentiviral Vif
proteins was found to be critical for the selective assembly and
activity of Vif-Cul5-E3 ligase and is required for Vif's interaction
with Cul5 (Luo et al., 2005).
Since inhibition of Vif-mediated hA3G degradation repre-
sents a new strategy for anti-HIV-1 therapy, defining motifs
within hA3G involved in the depletion is clearly desired. It has
been previously reported that a fragment of hA3G, consisting of
amino acids 54–124, is sufficient for the specific interaction with
HIV-1 Vif in transfected cells, but this fragment is resistant to
Vif-mediated degradation, suggesting that the association with
Vif is not sufficient for the degradation of human hA3G
(Conticello et al., 2003). HIV Vif efficiently neutralizes the
activity of APOBEC3G from human, but not fromAfrican green
monkeys (AGM). Similarly, the reverse is observed with
SIVAGM Vif (Mariani et al., 2003). Using human/AGM chimeric
proteins demonstrated that a single amino acid at position 128
determines the species-specific sensitivity of these proteins to
Vif-mediated degradation, and substituting this residue switches
specificities of Vif binding and Vif neutralization activity
(Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer
et al., 2004). Most recently, it has been shown that substitution
mutations in 3-amino-acid motif comprising aspartic acid–
proline–aspartic acid (DPD motif) at position 128 to 130
resulted in the inhibition of the Vif/hA3G interaction (Huthoff
and Malim, 2007). It remains unclear whether the DPD motif
plays a central role in the degradation of hA3G by Vif or whether
mutations at this position may interfere with Vif/hA3G complex
formation, due to the presence of either an inappropriate charge
or a conformation change.
To further define the structural requirement of hA3G for Vif-
mediated degradation, we have performed a function analysis of
the motifs within hA3G that are involved in the depletion. In this
work, we show that the removal of the N-terminal 104 amino
acids or the C-terminal 245–384 amino acid residues of hA3Ghas
no effect onVif-mediated degradation, whereas the deletion of the
N-terminal 156 amino acids abolishes the sensitivity of hA3G to
Vif by inhibiting the ability of hA3G to bind to Vif. The C-
terminal linker sequence in hA3G, amino acids 157–245, is also
required for Vif mediated degradation, but not for interaction
between hA3G and Vif. A small fragment of hA3G containing
amino acids 105–245 is sufficient for its degradation induced byVif, which indicates that the linker region plays a central role in
the depletion. The C-terminal linker sequence plays an important
role in the polyubiquitination of hA3G induced by Vif, possibly
through interacting with other cofactors required for the process.
We also show that, as a novel anti-HIV strategy, hA3G-derived
peptides can be used to block Vif's function, resulting in the
inhibition of wild-type HIV-1 replication.
Results
The linker sequence between the two zinc coordination motifs
in hA3G is required for its degradation induced by Vif
Although it is evident that Vif interacts with cytoplasmic
hA3G as part of a Vif–Cul5–SCF complex, resulting in the
Fig. 2. The ability of hA3G 105–245 to be degraded by Vif. Plasmids coding for
wild-type hA3G or hA3G 104–245 were transfected into 293T alone or co-
transfected with the plasmid coding for Vif in the presence or absence of the
proteasome inhibitor MG132. (A) Graphic representation of the wild-type and
mutant hA3G variants tested. The filled rectangles represent the two catalytic
sites in hA3G, and the numbers represent the amino acid positions. (B) Western
blots of lysates of transfected cells probed, respectively, with anti-HA (top), anti-
β-actin (middle) and anti-Vif (bottom). (C) Western blots of anti-HA
immunoprecipitates from cell lysates probed with anti-Vif.
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et al., 2003), the motifs within human hA3G involved in the
depletion are still unclear. To address the question, a series of
HA-tagged hA3G truncations were constructed, as graphically
represented in Fig. 1A, and used to either transfect 293T cells or
co-transfect with a plasmid coding for HIV-1 Vif. The
cytoplasmic expression of the different hA3G variants in the
presence or absence of Vif was determined by Western blots
probed with anti-HA and anti-β-actin. As shown in Fig. 1B,
full-length hA3G and N-terminal truncations of hA3G were
well expressed, while C-terminal truncations of hA3G appeared
reduced in expression, even in the absence of Vif (upper panel),
consistent with our previous report (Cen et al., 2004). Vif alone
is sufficient for triggering the degradation of human hA3G
(Fig. 1B, lane 2). The deletion of the N-terminal 104 amino
acids or the C-terminal 246–384 amino acids does not sig-
nificantly affect their ability to be degraded by Vif, whereas
deletions of the N-terminal 156 amino acids or C-terminal 157–
384 amino acids appear to make hA3G resistant to Vif-mediated
degradation. To further analyze the effect of N-or C-terminal
deletions of hA3G upon Vif-mediated degradation, the
expression ratio of the different hA3G variants in the presence
or absence of Vif was determined and normalized to a ratio of
1.00 for wild-type hA3G. These ratios are listed at the bottom of
the upper panel in Fig. 1B. The study shows that the deletion of
the N-terminal 1–156 or C-terminal 157–384 amino acids
resulted in an 81% and 88% reduction, respectively, in the
ability of these fragments to be degraded by Vif, while only
minor decreases were found among other truncated forms of
hA3G. These results indicate that amino acids 105–245, the
linker sequence between the two zinc coordination motifs in
hA3G, are required for Vif-mediated degradation.
The abilities of the different hA3G variants to bind to Vif were
assessed by co-immunoprecipitation with anti-HA. As shown in
Fig. 1C, only the deletion of the N-terminal 156 amino acids of
hA3G abolished the association with Vif (lane 6), and Vif remains
undetectable in the co-immunoprecipitate of this hA3G mutant,
even with longer film exposure of this blot or using double the
amount of cell lysate (results not shown). Thus, these results
suggest that the N-terminal region of the linker sequence, i.e.,
amino acids 105–156, is involved in the association between
hA3G and Vif and that the resistance to Vif-mediated degradation
of the C-terminal fragment, hA3G 157–384, results from its
failure to bind toVif. Furthermore, these data also indicate that the
association with Vif is not sufficient for the degradation of human
hA3G, i.e., the N-terminal fragment, hA3G 1–156 is able to bind
to Vif, but its expression is not affected by the presence of Vif.
Furthermore, we have assessed the ability of hA3G 105–245 to
bind toVif by co-immunoprecipitationwith anti-HA.As shown in
Fig. 2C, we found a similar amount of Vif present in the co-
immunoprecipitate of the hA3G mutant (lane 8), compared with
that of wild-type hA3G (lane 6) in the presence of a proteasome
inhibitor, MG132, while a reduced but significant amount of Vif
was co-immunoprecipitated with the hA3G mutant (lane 4),
probably due to much less cellular expression of hA3G 105–245
compared to wild type of hA3G in the absence of MG132
(Fig. 2B).Interestingly, while N-terminal fragments of hA3G appeared
reduced in expression (the upper panel of Fig. 1B), the amount
of Vif co-immunoprecipitated with these deletions did not
change significantly, compared with full-length hA3G (the
lower panel of Fig. 1C). Similarly, our previous work has shown
that the removal of the C-terminal regions of hA3G appears to
result in significant decreases in their concentration in the total
cell lysate without a similar quantitative decrease in their in-
corporation into Gag VLPs. These observations suggest that a
particular cellular compartment of the hA3G pool may be the
source of viral hA3G, which also interacts with Vif for its
degradation, so that the decreases in total mutated hA3G pools
may not reflect the changes in the source of viral hA3G.
The linker fragment of hA3G is sufficient for Vif-mediated
degradation
We next determined whether the linker fragment composed
of amino acids 105–245 of hA3G is sufficient to allow its
degradation by Vif. As shown in Fig. 2, the cytoplasmic
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in the presence or absence of Vif. The result (Fig. 2B) shows
that Vif is able to reduce the expression of this fragment to a
level similar to the reduction of wild-type hA3G, suggesting
that the linker sequence between two zinc coordination motifs is
sufficient for Vif-mediated degradation. When the transfected
cells were treated with the proteasome inhibitor MG132, the
expression of both wild-type and hA3G 105–245 appeared to
be unchanged in the presence or absence of Vif (Fig. 2, right
side), thereby confirming that the decrease in expression of the
linker fragment resulted from the proteasomal-dependent
degradation induced by Vif. Furthermore, we have assessed the
ability of hA3G 105–245 to bind to Vif by co-immunoprecip-
itation with anti-HA. As shown in Fig. 2C, a similar amount of
Vif present in the co-immunoprecipitate of the hA3G mutant
(lane 8), compared with that of wild-type hA3G (lane 6) in the
presence of MG132, suggests that both wild-type hA3G and
hA3G 105–245 bind with similar efficiency to Vif. In the
absence of MG132, a reduced, but significant, amount of Vif
was co-immunoprecipitated with the hA3G mutant (lane 4),
probably due to a lower cellular expression of hA3G 105–245
than wild-type hA3G (Fig. 2B).
In agreement with previous studies (Liu et al., 2004), the
addition of proteasome inhibitors did not affect the cellular
expression of wild-type hA3G (lanes 1 and 5, Fig. 2). Unlike
wild-type hA3G, MG132 treatment resulted in an increasing
cellular concentration of hA3G 105–245 in the absence of VifFig. 3. The effect of hA3G 1–156 or hA3G 157–384 upon Vif-mediated degradatio
(1 μg) and full-length hA3G (1 μg) and increasing amounts of plasmid expressing h
respectively). Western blots of lysates of transfected cells probed with anti-HA (top
hA3G, hA3G fragments and β-actin, respectively. (D) Quantitative analysis of Weste
as described in Experimentals and methods, and normalized to that in the absence o(lanes 3 and 7, Fig. 2), suggesting that this linker fragment is
inherently unstable, resulting in proteasome-dependent degra-
dation. Similarly, a pulse-chase analysis has shown that GFP
fusions with the N-terminal domain of hA3G were intrinsically
unstable without Vif (Conticello et al., 2003). Although hA3G
105–245 appears inherently unstable, it still exhibits Vif-
mediated degradation, indicating that the linker fragment
between the two zinc coordination motifs in hA3G is sufficient
for its degradation induced by Vif.
Effect of various hA3G fragments upon Vif-mediated
degradation of full-length hA3G
We have shown that the linker sequence within hA3G is
sufficient for its degradation induced by Vif, and the N-terminal
portion of this fragment acts as a Vif-binding motif. Vif can
reduce the expression of hA3G 105–245 (Fig. 2), but not hA3G
1–156 (Fig. 1), even though both hA3G fragments containing
amino acids 105–156 can bind to Vif. These results suggest that
the C-terminal region of the linker sequence, hA3G 157–245, is
also involved in facilitatingVif-mediated degradation. To further
clarity the function of the C-terminal region of the linker
sequence, we examined the effect of different hA3G fragments
upon Vif-mediated degradation of full-length hA3G. 293T cells
were co-transfected with plasmids coding for Vif, full-length
human hA3G and increasing amount of plasmids expressing
either hA3G 1–156 (Fig. 3A), hA3G 157–384 (Fig. 3B) orn of full-length hA3G. 293T cell were transfected with plasmids coding for Vif
A3G 1–156 (A), hA3G 157–384 (B) or hA3G 246–384 (C) (0.5, 1 and 2 μg,
and middle) and anti-β-actin (bottom) were produced for detecting full-length
rn blot data in panels A to C. The amounts of full-length hA3G were determined,
f Vif.
Fig. 4. The effect of hA3G 1–156 or hA3G 157–384 upon the interaction between Vif and full-length hA3G. 293T cells were transfected with plasmids coding for Vif,
HA-tagged full-length hA3G and Flag-tagged hA3G 1–156, hA3G 157–384 or hA3G 246–384. (A) Western blots of lysates of transfected cells probed, respectively,
with anti-HA (top), anti-Flag (middle) and anti-Vif (bottom). (B) Western blots of rabbit anti-HA immunoprecipitates from cell lysates probed with anti-Vif (upper) and
mouse anti-HA (bottom), respectively. (C) Western blots of rabbit anti-HA immunoprecipitates from cell lysates probed with anti-Myc (upper) and mouse anti-HA
(bottom), respectively.
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cytoplasmic expression of full-length hA3G was detected with
increasing expression of hA3G 1–156 or hA3G 157–384,
respectively, while the expression of hA3G 246–384 (Fig. 3C)
or co-transfection of the same amount of empty vector pcDNA3.1
(data not shown) had no effect upon the expression of full-length
hA3G. In the absence of Vif, increasing expression of either one
of these three hA3G fragment did not result in any increase in the
cellular expression of full-length hA3G (data not shown),
suggesting that both hA3G 1–156 and hA3G 157–384 can
dominantly block the Vif-mediated degradation of full-length
hA3G. The fact that expression of hA3G 246–384 was unable to
increase the expression of wild-type hA3G in the presence of Vif
further supports our conclusion that amino acids 157–245 of
hA3G is involved in the Vif-mediated degradation.
Since the binding of Vif to hA3G is a prerequisite for
facilitating the depletion of hA3G, we next determined whether
the blocking effect of hA3G fragments used on the degradation
results from interrupting the formation of Vif/hA3G complexes.
293T cell were co-transfected with plasmids coding for Vif,
HA-tagged full-length human hA3G, and Flag-tagged hA3G 1–
156 or hA3G 157–384. The effect of these hA3G fragments
upon the association of Vif and full-length wild-type hA3G was
analyzed using co-immunoprecipitation with anti-HA to detect
Vif/hA3G complexes. Results showed that a reduced amount of
Vif was co-immunoprecipitated with full-length hA3G, when
Flag-tagged hA3G 1–156, but not hA3G 157–384, was co-
expressed (Fig. 4), suggesting that the blocking effect of hA3G
1–156 on hA3G degradation results from a competitive binding
with full-length hA3G for Vif.
Interestingly, hA3G 157–384 can dominantly inhibit the Vif-
mediated degradation (Fig. 3B), even though it is unable to bind
to Vif (Fig. 1C) and to interrupt the interaction between Vif and
hA3G (Fig. 4B). To further define the mechanism of this
inhibition, we next examined the effect of hA3G 157–384 upon
the polyubiquitination of hA3G induced by Vif. hA3G was
immunoprecipitated with anti-HA from lysates of 293T cells
that also expressed Vif, HA-tagged full-length hA3G, Myc-tagged ubiquitin, and either Flag-tagged hA3G 157–384 or
hA3G 246–384. The polyubiquination of hA3G was detected
by Western blots of the co-immunoprecipitate probed with anti-
Myc. As shown in Fig. 4C, a significant reduction in the
polyubiquitination of hA3G was detected in the presence of
hA3G 157–384, while expression of hA3G 246–384 had no
effect on the polyubiquitination of hA3G. This result indicates
that amino acids 157–245 of hA3G is involved in hA3G
polyubiquitination induced by Vif, and blocking polyubiquiti-
nation by hA3G 157–384 results in the inhibition of Vif-
mediated hA3G degradation.
Lysine residues located within C-terminal portion of the linker
sequence are not required for Vif-mediated degradation of
hA3G fragments
Linking a chain of ubiquitin molecules to a specific lysine of
the target protein is a prerequisite for proteasome-dependent
protein degradation. We have found that the C-terminal linker
sequence in hA3G, amino acids 157–245, is required for Vif
mediated degradation, but not for interaction between hA3G and
Vif. Therefore we speculated that the lysine residues located
within, or close to, hA3G 157–245 (Lys150, Lys163 and Lys180)
may act as targets for polyubiquitination, and the removal of this
fragment may cause either direct loss of the polyubiquitination
site (Lys163 and Lys180) or inefficient polyubiquitination of
Lys150. To test this hypothesis, we introduced three Lys to Arg
mutations in hA3G 105–245 at position 150, 163 and 180,
thereby generating three mutated hA3G 105–245 fragments
named K150R, K163R and K180R. A fourth fragment, K150/
163/180R, contains all of three point mutations. We transfected
293T cells with either one of these hA3G mutant alone or co-
transfected these constructs with a plasmid coding for Vif. The
cytoplasmic expression of these hA3G mutants was analyzed in
the presence or absence of Vif. These results (Fig. 5) show that Vif
is able to reduce the expression of all hA3G mutants to levels
similar to the reduction of the wild-type hA3G 105–245,
suggesting that the Lys substitution mutation at the designated
Fig. 5. The effect of substitution mutations of lysine residues upon the
degradation of hA3G 105–245 by Vif. Plasmids coding for HA-tagged hA3G
105–245 and its mutants were transfected into 293Talone or co-transfected with
the plasmid coding for Vif. (A) Graphic representation of the hA3G 105–245
and its variants tested. The filled rectangles represent the two catalytic sites in
hA3G, and the numbers represent the amino acid positions. Lys (K) in hA3G
105–245 at positions 150, 163 and 180 were substituted with Arg (R) as
indicated. (B) Western blots of lysates of transfected cells probed, respectively,
with anti-HA (top), anti-β-actin (middle) and anti-Vif (bottom).
Fig. 6. Expression of hA3G 1–156 or hA3G 157–384 inhibits HIV-1 replication
in H9 cells. H9 and SupT1 cell lines were established, as described in
Experimentals and methods, that stably express either hA3G 1–156, hA3G 157–
384 or empty vector pcDNA3.1. (A) Western blots of cell lysates probed,
respectively, with anti-hA3G (top), anti-HA (middle) and anti-β-actin (bottom).
(B) 293T cells were transfected with wild-type HIV-1 BH10. Forty eight hours
post-transfection, cell-free supernatants containing 5 ng viral capsid (p24) were
used to infect 3×106 H9 cells stably expressing either hA3G 1–156, hA3G 157–
384 or empty vector pcDNA3.1, as indicated. Western blots of H9 cell lysates
(upper two panels) were probed with anti-hA3G (upper) or anti-β-actin (lower).
Western blots of viral lysates produced from H9 cells (lower two panels) were
probed with anti-hA3G (upper) or anti-p24 (lower). Non-infected H9 cells stably
expressing empty vector pcDNA3.1 were used as a control. (C and D) The stably
transfected H9 (C) and SupT1 (D) cell lines were infected with wild-type HIV-1,
as described above, and cultured over 15 days period post-infection. Additional
control groups include H9 and SupT1 cell line stably expressing hA3G 246–384
and infected with HIV-1, as well as H9 and SupT1 cells expressing empty vector
pcDNA3.1 and infected with Vif-negative HIV-1 (BH10.Vif(−)). Every 3 days,
the amounts of extracellular viral capsid (p24) were measured by ELISA and
plotted on a linear scale.
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the key role of hA3G 156–245 is not to provide polyubiquination
sites for use in the degradation process.
Expression of hA3G fragments inhibits HIV-1 replication in
non-permissive cells
Transient expression of hA3G fragments that block Vif-
mediated degradation might also inhibit wild-type HIV-1
replication in non-permissive cells by protecting endogenous
hA3G from Vif-induced degradation. Therefore, we have
analyzed the effect of hA3G fragments able to block Vif's
action upon the replication of wild-type HIV-1 in the H9 non-
permissive cell line that constitutively expressed wild-type
hA3G and in a permissive cell line SupT1. Stable H9 and SupT1
cell lines were established that constitutively expressed hA3G
1–156, hA3G 157–384, or empty vector. The cytoplasmic ex-
pression of the hA3G fragments in H9 and SupT1 cell lines was
determined by Western blots probed with anti-HA and anti-β-
actin. As shown in Fig. 6A, the expression of hA3G 1–156
appeared to be much lower than that of hA3G 157–384 in both
cell types, and expression of either hA3G fragments had no
effect on cellular content of endogenous hA3G determined by
Western blot probed with anti-hA3G.
These cell lines were then infected with the wild-type HIV-1
(BH10), and extracellular p24 was measured as a sign of viral
production. As shown in Fig. 6C, the similar amounts of
extracellular p24 produced from BH10-infected H9 cells and
the H9 cell line stably expressing either hA3G 246–384 orempty vector reached maximum concentrations at 12 days,
while the production of p24 in the medium of infected H9 cells
expressing either hA3G 1–156 or hA3G 157–384 is reduced to
34% and 12% of the control group, respectively. These results
show that both hA3G 1–156 and hA3G 157–384 inhibit wild-
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in the presence of Vif, despite the fact that their inhibition of
viral replication is still less than that resulted from the absence
of Vif, i.e., viral production of Vif-negative HIV-1 (BH10.Vif
(−)) in H9 cells is less than 3%. When SupT1 cell lines
described above were infected with wild-type HIV-1, the
inhibition of viral replication by the C-terminal hA3G 157–384
fragment was totally abolished, while expression of hA3G 1–
156 resulted in a 10% inhibition of viral replication (Fig. 6D).
The fact that both hA3G 1–156 and hA3G 157–384 are able to
inhibit the replication of wild-type HIV-1 effectively only in
non-permissive cells further supports our conclusion that these
two hA3G fragments dominantly block the Vif-mediated
degradation of full-length hA3G and also suggests that their
inhibition of HIV-1 replication resulted from preventing Vif-
mediated degradation of endogenous hA3G. In agreement with
this interpretation, Western blot analysis of infected cell lysate
showed that the amount of endogenous hA3G in H9 cells
expressing either hA3G 1–156 or hA3G 157–384 was
increased significantly, compared with that of H9 cells using a
control vector (Fig. 6B, upper two panels). Similarly, the
expression of either hA3G 1–156 or hA3G 157–384 in H9 cells
resulted in increased viral incorporation of endogenous hA3G,
i.e., 4 or 10 fold more than that found in virions produced from
H9 cells containing a control vector (Fig. 6B, lower two panels).
Although hA3G 1–156 and hA3G 157–384 showed similar
abilities to protect full-length hA3G from Vif-induced degra-
dation in the transient expression system (Fig. 3), the inhibitory
effect of hA3G 1–156 on HIV-1 replication is lower than that of
hA3G 157–384 in stably expressing cell lines (Fig. 6B),
probably due to the lower cellular expression of hA3G 1–156
(Fig. 6A). The low expression of hA3G 1–156 in the stably
transfected cell lines would also account for a minor (about
10%) inhibition of HIV-1 replication in the SupT1 cells, while
this hA3G fragment has been shown to produce more than 50%
of the anti-HIV activity produced with wild-type hA3G when
expressed at similar levels to wild-type hA3G (Guo et al.,
2006).
Discussion
The results presented here show that a key region in hA3G
that is required for its association with Vif includes amino acids
105–156 in the N-terminal part of the linker region between the
two zinc coordination motifs in hA3G. The ability of the N-
terminal fragment of hA3G to inhibit the Vif/hA3G interaction
and Vif-mediated hA3G degradation provides further support
for the conclusion that amino acids 105–156 in hA3G play an
important role in the interaction between Vif and hA3G. It has
also been reported that the hA3G binding site for Vif includes
amino acids 54–124 and that hA3G missing amino acids 1–67
still retains the ability to bind to Vif (Conticello et al., 2003). An
earlier work also reported that removal of 38 aa from the
C-terminus of hA3G abolished its association with Vif in 293T
cells stably expressing hA3G (Li et al., 2004). However, the
C-terminus of hA3B, which is unable to bind to HIV-1 Vif,
shows ∼90% sequence identity to this region in hA3G (34/38amino acids are identical), while the alignment analysis of
C-terminal fragments reveals that hA3G and hA3F, both
sensitive to HIV-1 Vif, are much more divergent (∼38%
homology), and all the conserved amino acid residues in both
molecules are also present in hA3B.
Recent data have shown that the N-terminal sequences of
hA3G are able to bind to Vif while remaining resistant to Vif-
induced depletion, suggesting that binding of Vif to hA3G is
required, but not sufficient, for hA3G degradation (Conticello
et al., 2003). We have also found that Vif is able to induce the
degradation of mutant hA3G missing the C-terminal 245–384
amino acids, but not degrade hA3G missing C-terminal amino
acids 157–384, even though both fragments are able to bind to
Vif. Furthermore, hA3G 157–384, but not hA3G 246–384, can
dominantly block the polyubiquitination and degradation of full-
length hA3G induced by Vif. These data indicate that amino
acids 157–245 (the C-terminal portion of linker sequence in
hA3G) are directly involved in Vif-mediated hA3G degradation
and that the resistance of the N-terminal hA3G (like hA3G 1–
156) to Vif is unlikely to be due to any conformational change
that might result from the removal of the C-terminal region. This
fragment is unable to bind to Vif (Fig. 1C) or to interrupt the
interaction between Vif and hA3G (Fig. 5B), and lysine residues
in this fragment are not required for its degradation by
polyubiquitination. Therefore, we speculate that there may be
a motif located between amino acids 157 and 245 that might
interact with some unknown cellular factors required for the
depletion process, and hA3G 157–245 might compete with full-
length hA3G to bind to these factors, thereby inhibiting the
degradation, as shown in Fig. 4. Another explanation is a
possible secondary interaction of amino acids 157–245 of hA3G
and the Vif–Cul5–SCF complex, which is crucial for the
formation of a functional complex for hA3G degradation, but
one that may be not significant enough to detect in the co-
immunoprecipitation assay.
Previous studies have shown that the incorporation of hA3G
into HIV-1 requires the N-terminal part of the linker sequence
between the two zinc coordination motifs in this protein, in
particular amino acids 105–156 (Cen et al., 2004). The same
region in hA3G has been found to facilitate interaction with
both Vif and HIV-1 Gag. This suggests that a competitive
binding between Vif and HIV-1 Gag for hA3G may occur
during viral assembly, which may further prevent viral
incorporation of hA3G, in addition to Vif-mediated degradation
of hA3G. In support of this hypothesis, evidence is presented
showing that production of infectious HIV-1 does not require
the full depletion of hA3G from the virus-producing cell (Kao
et al., 2004; Opi et al., 2007), implying that Vif-mediated hA3G
degradation may not be a sole mechanism of blocking viral
incorporation of hA3G.
The mechanism by which Vif mediates hA3G degradation is
a novel target for anti-HIV-1 drug development. We have shown
herein that hA3G fragments will dominantly block the Vif-
mediated degradation of hA3G, resulting in the protection of
endogenous hA3G from Vif-mediated degradation and resulting
in the inhibition of HIV-1 replication, even in the presence of
Vif.
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Plasmid construction
SVC21BH10 is a simian virus 40-based vector that contains
full-length wild-type HIV-1 proviral DNA. The sequence
coding for full-length Vif was amplified by PCR from
SVC21.BH10 and inserted into pcDNA3.1. The cDNA frag-
ment coding for hA3G was cloned into the pcDNA3.1 V5/His A
vector (Invitrogen), which expresses wild-type and mutant
forms of hA3G with a fused HA tag at the C-terminus, as
previously described (Cen et al., 2004). In order to construct
mutant hA3G 105–245, cDNA sequence coding for amino
acids 105–245 of hA3G was PCR-amplified and cloned into the
EcoRI and XhoI sites of the pcDNA3.1 V5/His A vector with a
fused HA tag at the C-terminus, as previously described (Cen
et al., 2004). The cDNA fragment coding for hA3G amino acid
1–156, 157–384 or 246–384 was PCR-amplified and intro-
duced a Flag tag at the C-terminus of each fragment, which was
placed in each of the reverse PCR primers. These fragments
were cloned into the pcDNA3.1 V5/His A vector, and the
resulting constructs express Flag-tagged truncated hA3G.
K150R, K163R and K180R codes for hA3G 105–245 con-
taining Lys to Arg mutations at either position 150, 163 and
180, respectively, and were constructed using oligonucleotide
site-directed mutagenesis (Invitrogen). K150/163/180R con-
tains all of three point mutations. Ub-Myc coding for a Myc-
tagged ubiquitin was a gift from Xiao-Fang Yu (Johns Hopkins
University) and was constructed, as previously described (Yu
et al., 2003).
Cells, transfections and viruses purification
The culture and transfection of HEK-293T cells with these
plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad,
California), and the isolation of virions 48 h post-transfection
from the cell supernatant, were done as previously described
(Cen et al., 2004; Guo et al., 2006). To establish H9 and SupT1
cell lines stably expressing hA3G fragments, H9 or SupT1 cells
were transfected with empty vector or plasmids expressing
either hA3G 1–156, 157–384 or 246–384, using Lipofecta-
mine (Invitrogen, Carlsbad, California), and stable cell lines
were selected with 1 mg of G418 (Invitrogen) per ml for 2
weeks. Expression of hA3G fragments in H9 and SupT1 cell
lines was confirmed by Western blots probed with the anti-HA
antibody.
Protein analysis
Cellular and viral proteins were extracted with RIPA buffer
(10 mM Tris, pH 7.4, 100 mM NaCl, 1% sodium deoxycholate,
0.1% SDS, 1% NP40, 2 mg/ml aprotinin, 2 mg/ml leupeptin, 1
mg/ml pepstatin A, 100 mg/ml PMSF). The cell lysates were
analyzed by SDS–PAGE (10% acrylamide) followed by blotting
onto nitrocellulose membranes (Amersham Pharmacia). West-
ern blots were probed with monoclonal antibodies that are
specifically reactive with HIV-1 capsid (p24) (Zepto MetrocsInc.), hA3G (NIH AIDS Research and Reference Reagent
Program), hemagglutinin (HA; Santa Cruz Biotechnology, Inc.),
Flag (Sigma Inc.) and β-actin (Sigma) or with Vif-specific
polyclonal antiserum (NIH AIDS Research and Reference
Reagent Program). Detection of proteins was performed by
enhanced chemiluminescence (NEN Life Sciences Products),
using as secondary antibodies anti-mouse (for hA3G, p24 andβ-
actin) and anti-rabbit (for Flag, HA and Vif), both obtained from
Amersham Life Sciences.
Immunoprecipitation assay
293T cells from 100 mm plates were collected 48 h post-
transfection and lysed in 500 μl TNT buffer (20 mM Tris–HCl
pH 7.5, 200 mM NaCl, 1% Triton X-100). Insoluble material
was pelleted at 1800×g for 30 min. The supernatant was used as
the source of immunoprecipitated Vif/APOBEC3G complexes.
Equal amounts of protein were incubated with 5 μl HA-specific
monoclonal antibody for 16 h at 4 °C followed by the addition
of protein A–Sepharose (Pharmacia) for 2 h. For a Western blot
of different lysates, 500 μg of lysate protein was used for
immunoprecipitation of each sample, while for different
nuclease experiments on the same lysate sample, approximately
200 μg of lysate protein was used for immunoprecipitation.
Lysate protein was determined by the BioRad assay. The
immunoprecipitate was then washed three times with TNT
buffer and twice with phosphate-buffered saline (PBS). After
the final supernatant was removed, 30 μl of 2× sample buffer
(120 mM Tris HCl, pH 6.8, 20% glycerol, 4% SDS, 2% β-
mercaptoethanol and 0.02% bromphenol blue) was added, and
the precipitate was then boiled for 5 min to release the
precipitated proteins. After microcentrifugation, the resulting
supernatant was analyzed using Western blots, as previously
described (Khorchid et al., 2002). For analysis of the
polyubiquitination of hA3G induced by Vif, the 293T cells
were transfected with plasmids expressing Vif, Myc-tagged
ubiquitin (ub-Myc) and HA-tagged hA3G. Cells were lysed,
and lysates were immunoprecipitated with anti-HA and
analyzed by Western blot probed with anti-Myc, as previously
described (Yu et al., 2003).
HIV-1 infectivity analysis
p24 in virus-containing supernatants was quantitated by
enzyme-linked immunosorbent assay (Guo et al., 2003).
Viruses normalized by p24 were added to H9 or SupT1 cell
lines, and HIV-1 replication was determined by measuring the
amount of p24 in the culture supernatant with an HIV-1 p24
enzyme-linked immunosorbent assay kit, as previously de-
scribed (Guo et al., 2003).
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